Thrombophilia in children with venous thromboembolic disease

Thrombosis Research

Volumn 118, Issue 1, 2006, Pages 59-65

  Revel Vilk, Shoshana ^a   Kenet, Gili ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Pediatric; Thrombophilia; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; GLYCOPROTEIN; HEPARIN COFACTOR II; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; CATHETER THROMBOSIS; CHILDHOOD CANCER; CHILDHOOD DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FULMINATING PURPURA; GENE MUTATION; GENETIC RISK; HOMOCYSTINURIA; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; LONG TERM CARE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REGISTER; REVIEW; RISK FACTOR; SCREENING; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT INDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; BLOOD; CHILD; INFANT; PRESCHOOL CHILD; THROMBOEMBOLISM; VEIN THROMBOSIS;

BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PRACTICE GUIDELINES; PROGNOSIS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33747614313     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.05.026     Document Type: Review

References (63)

1. Pineo G.F., and Hull R.D. Thrombophilia: disorders predisposing to venous thromboembolism. Baillieres Clin Haematol 11 (1998) 525-540
2. von Depka M., Nowak-Gottl U., Eisert R., Dieterich C., Barthels M., Scharrer I., et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96 (2000) 3364-3368
3. Nowak-Gottl U., Junker R., Hartmeier M., Koch H.G., Munchow N., Assmann G., et al. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 100 (1999) 743-748
4. den Heijer M., and Keijzer M.B. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med 39 (2001) 710-713
5. Kraaijenhagen R.A., Anker P.S., Koopman M.M.W., Reitsma P.H., Prins M.H., van den Ende A., et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83 (2000) 5-9
6. Meijers J.C.M., Tekelenburg W.L.H., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342 (2000) 696-701
7. van Hylckama Vlieg A., vander Linden I.K., Bertina R.M., and Rosendaal F.R. High levels of factor IX increase the risk of venous thrombosis. Blood 95 (2000) 3678-3682
8. Revel-Vilk S., Chan A., Bauman M., and Massicotte P. Incidence of congenital prothrombotic disorders in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 1 (2003) 915-921
9. Goldenberg N.A., Knapp-Clevenger R., Manco-Johnson M.J., and Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 351 (2004) 1081-1088
10. Greaves M., Cohen H., Machin S.J., and Mackie I. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 109 (2000) 704-715
11. Andrew M., David M., Adams M., Ali K., Anderson R., Barnard D., et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83 (1994) 1251-1257
12. Ehrenforth S., Junker R., Koch H.G., Kreuz W., Munchow N., Scharrer I., et al. Multicenter evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 158 Supp 3 (1999) S97-S104
13. van Ommen C.H., Heijboer H., Buller H.R., Hirasing R.A., Heijmans H.S.A., and Peters M. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Pediatr 139 (2001) 676-681
14. Bonduel M., Hepner M., Sciuccati G., Pieroni G., Torres A.F., Maradarz C., et al. Factor V Leiden and prothrombotic gene G20210A mutation in children with venous thromboembolism. Thromb Haemost 87 (2002) 972-977
15. Nowak-Gottl U., Dubbers A., Kececioglu D., Koch H.G., Kotthoff S., Runde J., et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 131 (1997) 608-612
16. Hagstrom J.N., Walter J., Bluebond-Langner R., Amatniek J.C., Manno C.S., and High K.A. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr 133 (1998) 777-781
17. Lawson S.E., Butler D., Enayat M.S., and Williams M.D. Congenital thrombophilia and thrombosis: a study in a single center. Arch Dis Child 81 (1999) 176-178
18. Heller C., Becker S., Scharrer I., and Kreuz W. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur J Pediatr 158 Suppl. 3 (1999) S117-S121
19. Kosch A., von Kries R., and Nowak-Gottl U. Thrombosen im kindesalter. Mon.schr Kinderheilkd 148 (2000) 387-397
20. Kosch A., Junker R., Kurnik K., Schobess R., Gunther G., Koch H., et al. Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 99 (2000) 531-537
21. Levins J.S., Branch W.B., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752-763
22. Berube C., Mitchell L., Silverman E., David M., Saint Cyr C., Laxer R., et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Pediatr Res 44 (1998) 351-356
23. Schmugge M., Revel-Vilk S., Hiraki L., Rand M.L., Blanchette V.S., and Silverman E.D. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr 143 (2003) 666-669
24. deVeber G., Monagle P., Chan A., MacGregor D., Curtis R., Lee S., et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 55 (1998) 1539-1543
25. Kenet G., Sadetzki S., Murad H., Martinowitz U., Rosenberg N., Gitel S., et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 31 (2000) 1283-1288
26. Heller C., Heinecke A., Junker R., Knofler R., Kosch A., Kurnik K., et al. Childhood Stroke Study Group. Cerebral venous thrombosis in children: a multifactorial origin. Circulation 108 (2003) 1362-1367
27. Munchow N., Kosch A., Schobess R., Junker R., Auberger K., and Nowak-Gottl U. Role of genetic prothrombotic risk factors in childhood caval vein thrombosis. Eur J Pediatr 158 Suppl. 3 (1999) S109-S112
28. Heller C., Schobess R., Kurnik K., Junker R., Gunther G., Kreuz W., et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors-a multicentre case-control study. Br J Haematol 111 (2000) 534-539
29. Kuhle S., Massicotte P., Chan A., and Mitchell L. A case series of 72 neonates with renal vein thrombosis. Data from the 1-800-NO-CLOTS Registry. Thromb Haemost 92 (2004) 729-733
30. Ruud E., Holmstrom H., Natvig S., and Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in children with cancer-a prospective study. Med Pediatr Oncol 38 (2002) 405-410
31. Leebeek F.W., Stadhouders N.A., van Stein D., Gomez-Garcia E.B., and Kappers-Klunne M.C. Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol 67 (2001) 15-19
32. Margaglione M., Brancaccio V., Ciampa A., Papa M.L., Grandone E., and Di Minno G. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings. Haematologica 86 (2001) 634-639
33. Ratcliffe M., Broadfoot C., Davidson M.M., Kelly K.F., and Greaves M. Thrombosis, markers of thrombotic risk, indwelling central venous catheter and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol 21 (1999) 353-357
34. Tesselaar M.E., Ouwerkerk J., Nooy M.A., Rosendaal F.R., and Osanto S. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40 (2004) 2253-2259
35. Athale U.A., and Chan A.K.C. Thrombosis in children with acute lymphoblastic leukemia: Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res 111 (2003) 321-327
36. Nowak-Gottl U., Wermes C., Junker R., Koch H.G., Schobess R., Fleischhack G., et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93 (1999) 1595-1599
37. Wermes C., von Depka Prondzinski M., Lichtinghagen R., Barthels M., Welte K., and Sykora K.W. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 158 Suppl. 3 (1999) S143-S146
38. Mauz-Korholz C., Junker R., Gobel U., and Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 83 6 (2000) 840-843
39. Mitchell L.G., Andrew M., Hanna K., Abshire T., Halton J., Anderson R., et al. Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with l-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97 (2003) 508-516
40. van Ommen C.H., Heijboer H., van den Dool E.J., Hutten B.A., and Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 1 (2003) 2516-2522
41. Rees D.C., Cox M., and Clegg J.B. World distribution of factor V Leiden. Lancet 346 (1995) 1133-1134
42. Rosendaal F.R., Doggen C.J.M., Zivelin A., Arruda V.R., Aiach M., Siscovick D.S., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79 (1998) 706-708
43. Andrew M.E., Mongale P., deVeber G., and Chan A.K. Thromboembolic disease and antithrombotic therapy in newborns. Hematology (Am Soc Hematol) Educ Program (2001) 358-374
44. Monagle P., Michelson A.D., Bovill E., and Andrew M. Antithrombotic therapy in children. Chest 119 (2001) S344-S370
45. Nowak-Gottl U., Junker R., Kreuz W., von Eckardstein A., Kosch A., Nohe N., et al. Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 97 (2001) 858-862
46. Pradoni P., Lesing A.W.A., Prins M.H., Frulla M., Marchiori A., Bernardi E., et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141 (2004) 249-256
47. Kuhle S., Koloshuk B., Marzinotto V., Bauman M., Massicotte M., Andrew M., et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 111 (2003) 227-233
48. Tormene D., Simioni P., Prandoni P., Francesca F., Zerbinati P., Togin G., et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 100 (2002) 2403-2405
49. Bucciarelli P., Rosendaal F.R., Tripodi A., Mannucci P.M., De Stefano V., Palareti G., et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 19 (1999) 1026-1033
50. Simioni P., Sanson B.J., Pradoni P., Tormene D., Friederich P.W., Girolami B., et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 81 (1999) 198-202
51. Martinelli I., Mannucci P.M., De Stefano V., Taioli E., Rossi V., Crosti F., et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 92 (1998) 2353-2358
52. Vossen C.Y., Conard J., Fontcuberta J., Makris M., Van der Meer F.J., Pabinger I., et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 3 (2005) 459-464
53. Greaves M., and Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease. Br J Haematol 109 (2000) 699-703
54. Walker I.D., Greaves M., and Preston F.E. Investigation and management of heritable thrombophilia. Br J Haematol 114 (2001) 512-528
55. Seligsohn U., and Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 344 (2001) 1222-1231
56. Kearon C., Crowther M., and Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 51 (2000) 169-185
57. Manco-Johnson MJGEF, Hellgreen M, Kemahli AS, Massciotte MP, Muntean W, Peters M, et al. Laboratory testing for thrombophilia in pediatric patients. Posted on ISTH Website.
58. Lensen R.P., Rosendaal F.R., Koster T., Allaart C.F., de Ronde H., Vandenbroucke J.P., et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 88 (1996) 4205-4208
59. Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 98 (2001) 20-21
60. Mannucci P.M. Genetic hypercoagulability: prevention suggests testing family members. Blood 98 (2001) 21-22
61. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 1 (2003) 410-411
62. Machin S.J. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 1 (2003) 412-413
63. Sutor A.H. Screening children with thrombosis for thrombophilic proteins. Cui bono?. J Thromb Haemost 1 (2003) 886-888